Lucenxia Malaysia, a subsidiary of Adventa Bhd, has launched the Lucenxia INTELLIS, an Intelligent Automated Peritoneal Dialysis (APD) cycler designed for patients with chronic kidney disease (CKD) to be treated at home, while they are asleep. This is to provide new hope and enhance quality of life of patients. The LUCENXIA INTELLIS APD is one of the treatment modalities that will help ease the strain on resources catering to the rapidly growing number of CKD patients in Malaysia.
Peritoneal Dialysis (PD) is a lesser known dialysis treatment in Malaysia compared to the more widely used hemodialysis. More than 90 percent of patients who undergo dialysis in Malaysia receive hemodialysis treatment. The average CKD patient receives 3 treatments at hemodialysis centers every week, with each session lasting between three to five hours. While PD allows for patients to receive treatment at the comfort of their own home.
Dialysis at home can greatly improve quality of life, which allows patients to regain control of their life. Unlike in-center hemodialysis, a more common blood-filtering procedure, PD utilizes the patient’s peritoneal membrane in the abdomen to remove excess fluid from the body. PD easily fits into a patient’s daily life due to its versatility and safety. There are many benefits to a patient’s physical and mental health associated with this type of treatment. A PD patient is able to be dialyzed at home, at work, or even while traveling. They have flexible treatment times, and most are able to eat a more regular diet, allowing them to continue living a more normal life.
As a result of their Universal Health Care commitment, several countries (Thailand and Hong Kong, in particular) have successfully enacted the Peritoneal Dialysis First policy as their primary treatment for renal diseases. Malaysia is currently exploring the roadmap to adopt a Peritoneal Dialysis First Policy.
Lucenxia with the INTELLIS APD cycler seeks to improve accessibility, outcomes, affordability, operational ease, and environmental protection while providing peritoneal dialysis services to more CKD patients so that they can have new hope and enjoy a better quality of life, including continuing to work independently, enjoying better mobility and be less bound by hemodialysis services. In addition, Lucenxia INTELLIS comes with full telemedicine functions, including online daily monitoring instead quarterly, early detection, enhanced safety, as well as automatic configuration through prescription that is administered online.
According to Lucenxia’s Managing Director, Mr. Low Chin Guan, “Lucenxia INTELLIS is a Malaysian innovation that will greatly benefit Malaysians, and soon to the rest of the world. We expect to see INTELLIS fulfilling the government’s vision of delivering better clinical outcomes for CKD patients. As Malaysia focuses more on research-driven healthcare, INTELLIS is one of our first and most impressive contributions to global healthcare.” he said.
Mr. Low added that the company is committed to providing hope and affordable health care solutions that can improve quality of life.
“Lucenxia is committed to creating and delivering technologies that can reduce barriers to treatment, enhance and extend the lives of patients, while improving quality of living around the world, and reduce healthcare costs. In the case of hemodialysis, both the cost and lack of mobility of current systems have made broader access to dialysis treatment difficult and expensive. Our goal and success with the INTELLIS APD cycler is to build a unique, internally developed system that will be portable, will lower costs, and will be more efficient in its use and other critical features than existing dialysis systems,” he explained.
Note: The INTELLIS APD Cycler can only be used upon your physician’s advice.